$16.42
Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
CryoPort to Provide IntegriCell Cryopreservation Services for Verismo's Development Programs
Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
Cryoport (CYRX) Stock Fair Value Rises After Analysts Revisit Bioservices Outlook
Overview
52-week range
$6.05
$17
97% of range
Avg surprise (last 3)
-18.6%
Avg reaction (last 2)
+0.4%
50% positive
Latest IV / EM
71%
EM ±16.1% · $18 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 4, 2026 | Mar/2026 | $-0.23 | $-0.20 | -15.0% | -4.5% | -1.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.18 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.29 | $-0.20 | -45.0% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-0.22 | $-0.23 | +4.3% | — | +2.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.02 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.62 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.43 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.31 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.42 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.20 | -$0.29 | +31.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48M | — | $44M | $45M | $41M | — | $38M | $40M |
| Cost of revenue | $26M | — | $23M | $24M | $22M | — | $21M | $22M |
| Gross profit | $22M | — | $21M | $21M | $19M | — | $17M | $18M |
| Operating income | $-10M | — | $-10M | $-10M | $-7M | — | $-13M | $-78M |
| Net income | $-11M | — | $-7M | $105M | $-12M | — | $805,000 | $-78M |
| EPS (diluted) | $-0.25 | — | $-0.18 | $2.05 | $-0.28 | — | $-0.02 | $-1.62 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $273M | $250M | $256M | $243M | $36M | $34M | $31M | $34M |
| Inventory | $22M | $23M | $23M | $23M | $23M | $21M | $24M | $24M |
| Total current assets | $471M | $476M | $485M | $489M | $411M | $342M | $350M | $502M |
| Total assets | $764M | $765M | $774M | $774M | $700M | $703M | $702M | $852M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $269M | $262M | $261M | $259M | $301M | $302M | $283M | $452M |
| Total equity | $495M | $503M | $513M | $519M | $399M | $402M | $419M | $400M |